全髋与全膝关节置换术HOOS-JR和KOOS-JR的MCID因支付类型而异
本研究基于852例THA和1439例TKA患者,按支付类型(商业保险、Medicare、Medicaid)分组,采用分布法(0.5×标准差)通过1000次 bootstrap 计算HOOS-JR和KOOS-JR的MCID。结果显示Medicaid患者MCID显著更高(HOOS-JR 12.6 vs 9.1/8.9;KOOS-JR 11.9 vs 8.8/9.0,P<0.001),提示统一阈值可能误判医院表现。
要点
- Medicaid患者THA后HOOS-JR的MCID为12.6,高于商业保险9.1和Medicare 8.9。
- Medicaid患者TKA后KOOS-JR的MCID为11.9,高于商业保险8.8和Medicare 9.0。
- 不同支付类型间MCID差异有统计学意义(ANOVA和Kruskal-Wallis检验P<0.001)。
核心结论
- HOOS-JR和KOOS-JR的MCID在不同支付类型间不一致,Medicaid患者在THA和TKA后MCID显著更高。
- 对异质性患者群体应用统一PROM阈值并强制公开达标率,可能歪曲医院和提供者的实际表现。
研究设计与样本
- 回顾性队列研究,纳入852例THA和1439例TKA患者,分别具有术前和术后1年的HOOS-JR和KOOS-JR评分。
- 按支付类型分为商业保险、Medicare(含Medicare Replacement)和Medicaid三组。
- 采用分布法(0.5×HOOS-JR/KOOS-JR标准差)通过1000次bootstrap迭代计算各组MCID,并用ANOVA和Kruskal-Wallis检验比较。
主要发现
- HOOS-JR的bootstrap MCID均值:商业保险9.1,Medicare 8.9,Medicaid 12.6,组间比较P<0.001。
- KOOS-JR的bootstrap MCID均值:商业保险8.8,Medicare 9.0,Medicaid 11.9,组间比较P<0.001。
关键数值与推荐
- HOOS-JR MCID阈值:商业保险9.1,Medicare 8.9,Medicaid 12.6。
- KOOS-JR MCID阈值:商业保险8.8,Medicare 9.0,Medicaid 11.9。
- MCID计算采用0.5×标准差分布法,bootstrap每组1000次迭代。
临床怎么用
- 临床解读THA/TKA患者PROM达标情况时,应考虑支付类型对MCID的影响,避免统一阈值造成偏差。
- 针对Medicaid患者,可能需要更高的MCID阈值来定义临床重要改善。
- 医院在公开报告PROM达标率时,应结合服务人群的支付类型构成进行风险调整。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent mandates from the Centers for Medicare and Medicaid Services have tied patient-reported outcome measure (PROM) metrics to hospital reimbursement for total hip arthroplasty (THA) and total knee arthroplasty (TKA). Concurrently, the proportion of patients meeting certain PROM metrics at each hospital will be publicly available. Threshold values such as the minimal clinically important difference (MCID) may vary across patient subpopulations. The Centers for Medicare and Medicaid Services proposal to apply blanket threshold values to all hospitals may skew results depending on the population being served. We hypothesized that socioeconomic parameters, such as insurance type, may influence thresholds, such as MCID for the Hip Disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS-JR), and Knee Disability and Osteoarthritis Outcome Score, Joint Replacement (KOOS-JR). METHODS: There were 852 THA and 1,439 TKA patients who had HOOS-JR and KOOS-JR scores at preoperative and 1-year time points, respectively, and were categorized by payer type: commercial, Medicare (including Medicare Replacement), and Medicaid. The MCID thresholds for each payer were calculated using a distribution-based method (0.5 × SD of H/KOOS-JR) via a bootstrapping procedure with 1,000 iterations per group and random sampling. The results were then compared with both analyses of variance (ANOVA) and Kruskal-Wallis tests. RESULTS: The mean HOOS-JR bootstrapped MCIDs for commercial, Medicare, and Medicaid were 9.1, 8.9, and 12.6, respectively. Both ANOVA and Kruskal-Wallis tests were statistically significant (P < 0.001). The mean KOOS-JR bootstrapped MCIDs for commercial, Medicare, and Medicaid were 8.8, 9.0, and 11.9, respectively. Both ANOVA and Kruskal-Wallis tests were statistically significant (P < 0.001). CONCLUSIONS: The MCIDs for HOOS-JR and KOOS-JR are not uniform across payer types. Specifically, Medicaid patients have significantly higher MCIDs following THA and TKA. Applying universal PROM thresholds across heterogeneous patient populations and mandating public reporting of those rates of achieving those thresholds may misrepresent hospitals and providers depending on the subpopulations served.
引用
- Pfeil AN, Hryc CF, Patel AR, et al. Hip and Knee Disability and Osteoarthritis Outcome Scores Minimal Clinically Important Differences Vary by Payer Type: Implications for Mandatory Patient-Reported Outcome Reporting. J Arthroplasty. 2026. PMID: 42001911. doi:10.1016/j.arth.2026.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。